<p> India’s drug regulator has granted approval for clinical trials of the first indigenously developed vaccine candidate against Covid-19.</p>.<p>The vaccine candidate Covaxin is developed by Bharat Biotech using the Covid-19 genome isolated by the National Institute of Virology, a Pune-based research facility under the aegis of Indian Council of Medical Research.</p>.<p>“We are proud to announce COVAXIN, India’s first indigenous vaccine against Covid-19,” Krishna Ella, Chairman and Managing Director of Bharat Biotech said in a statement.</p>.<p>It said the Drug Controller General of India has granted permission to initiate Phase I & II human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response.</p>.<p>Human clinical trials are scheduled to start across India in July 2020, the statement added.</p>.<p>Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies, Ella said adding that the results from these studies have been promising and show extensive safety and effective immune responses.</p>.<p>A number of drug manufacturers across the globe are working to find a cure for Covid-19, but no pharmaceutical firm has succeeded yet.</p>.<p>According to the World Health Organisation (WHO), of the 140 vaccines at different stages of development worldover, 16 are currently in late-stage clinical trials.</p>.<p>Of these 16 vaccine candidates, five are being researched in China, three in the US, two in the UK, and one each in Australia, Germany, and Russia.</p>
<p> India’s drug regulator has granted approval for clinical trials of the first indigenously developed vaccine candidate against Covid-19.</p>.<p>The vaccine candidate Covaxin is developed by Bharat Biotech using the Covid-19 genome isolated by the National Institute of Virology, a Pune-based research facility under the aegis of Indian Council of Medical Research.</p>.<p>“We are proud to announce COVAXIN, India’s first indigenous vaccine against Covid-19,” Krishna Ella, Chairman and Managing Director of Bharat Biotech said in a statement.</p>.<p>It said the Drug Controller General of India has granted permission to initiate Phase I & II human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response.</p>.<p>Human clinical trials are scheduled to start across India in July 2020, the statement added.</p>.<p>Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies, Ella said adding that the results from these studies have been promising and show extensive safety and effective immune responses.</p>.<p>A number of drug manufacturers across the globe are working to find a cure for Covid-19, but no pharmaceutical firm has succeeded yet.</p>.<p>According to the World Health Organisation (WHO), of the 140 vaccines at different stages of development worldover, 16 are currently in late-stage clinical trials.</p>.<p>Of these 16 vaccine candidates, five are being researched in China, three in the US, two in the UK, and one each in Australia, Germany, and Russia.</p>
